"000277325800022" . "9"^^ . . "0361-8609" . "3"^^ . . . "Persistent splenomegaly during imatinib therapy and the definition of complete hematological response in chronic myelogenous leukemia"@en . . "R\u00E1\u010Dil, Zden\u011Bk" . "US - Spojen\u00E9 st\u00E1ty americk\u00E9" . "\u017D\u00E1\u010Dkov\u00E1, Daniela" . "Persistent splenomegaly during imatinib therapy and the definition of complete hematological response in chronic myelogenous leukemia" . "Persistent splenomegaly during imatinib therapy and the definition of complete hematological response in chronic myelogenous leukemia" . . "Mayer, Ji\u0159\u00ED" . . "5" . . . "V, Z(MSM0021622430), Z(MSM6198959205)" . "Persistent splenomegaly during imatinib therapy and the definition of complete hematological response in chronic myelogenous leukemia"@en . "[0D4206D87853]" . . . "R\u00E1zga, Filip" . "278569" . . "85" . "splenomegaly"@en . "Splenomegaly belongs among typical findings on physical examination in patients with newly diagnosed chronic myelogenous leukemia (CML). Its disappearance is a part of achieving complete hematological response (CHR), that is nowadays (when second generation of tyrosine kinase inhibitors are available) of particular interest during imatinib treatment."@en . . . . "4"^^ . "American Journal of Hematology" . . "RIV/65269705:_____/10:#0001018" . "Splenomegaly belongs among typical findings on physical examination in patients with newly diagnosed chronic myelogenous leukemia (CML). Its disappearance is a part of achieving complete hematological response (CHR), that is nowadays (when second generation of tyrosine kinase inhibitors are available) of particular interest during imatinib treatment." . . . . "RIV/65269705:_____/10:#0001018!RIV11-MZ0-65269705" .